<?xml version="1.0" encoding="UTF-8" standalone="yes"?><drugRecordsOutput><serviceExecutionTime>354</serviceExecutionTime><Drug id="64571"><DrugName>bococizumab</DrugName><DrugNamesKey><Name id="43021481">bococizumab</Name></DrugNamesKey><DrugSynonyms><Name><Value>RN-316</Value><Types><Type>Research Code</Type></Types></Name><Name><Value>proprotein convertase subtilisin/kexin type 9 targeted monoclonal antibody (hypercholesterolemia), Pfizer</Value></Name><Name><Value>anti-PCSK9 mAb (hypercholesterolemia), Pfizer</Value></Name><Name><Value>PCSK9-targeted monoclonal antibody (hypercholesterolemia), Pfizer</Value></Name><Name><Value>PF-04950615</Value><Types><Type>Research Code</Type></Types></Name><Name><Value>bococizumab</Value><Types><Type>USAN</Type><Type>INN</Type></Types></Name></DrugSynonyms><CompanyOriginator id="18767">Pfizer Inc</CompanyOriginator><CompaniesSecondary><Company id="18767">Pfizer Inc</Company></CompaniesSecondary><CrossReferences><SourceEntity id="64571" type="Drug"><TargetEntity id="706124" type="siDrug">Bococizumab</TargetEntity></SourceEntity><SourceEntity id="18767" type="Company"><TargetEntity id="4295904722" type="organizationId">Pfizer Inc</TargetEntity></SourceEntity><SourceEntity id="174" type="ciIndication"><TargetEntity id="10020603" type="MEDDRA"/><TargetEntity id="D006937" type="MeSH"/><TargetEntity id="-1478187279" type="omicsDisease"/><TargetEntity id="969" type="siCondition"/></SourceEntity><SourceEntity id="175" type="ciIndication"><TargetEntity id="10062060" type="MEDDRA"/><TargetEntity id="D006949" type="MeSH"/><TargetEntity id="-1908196798" type="omicsDisease"/><TargetEntity id="971" type="siCondition"/></SourceEntity><SourceEntity id="3204" type="ciIndication"><TargetEntity id="970" type="siCondition"/></SourceEntity><SourceEntity id="48843" type="Action"><TargetEntity id="3596" type="Mechanism">Proprotein Convertase Subtilisin/Kexin-Type 9 (PCSK9) Inhibitors</TargetEntity><TargetEntity id="3673" type="Mechanism">Anti-PCSK9 (Proprotein Convertase Subtilisin/Kexin-Type 9)</TargetEntity></SourceEntity><SourceEntity id="71" type="Action"><TargetEntity id="693" type="Mechanism">Cholesterol Absorption Inhibitors</TargetEntity></SourceEntity><SourceEntity id="PTGT-08850" type="ciTarget"><TargetEntity id="10271182557383" type="siTarget">Proprotein convertase subtilisin/kexin type 9</TargetEntity><TargetEntity id="-1649621866" type="omicsTarget"/></SourceEntity></CrossReferences><PhaseHighest id="DX">Discontinued</PhaseHighest><PhaseTerminated id="C3">Phase 3 Clinical</PhaseTerminated><IndicationsSecondary><Indication id="174">Hypercholesterolemia</Indication><Indication id="175">Hyperlipidemia</Indication><Indication id="3204">Familial hypercholesterolemia</Indication></IndicationsSecondary><ActionsPrimary><Action id="48843">Proprotein convertase PC9 inhibitor</Action></ActionsPrimary><ActionsSecondary><Action id="2516">LDL cholesterol modulator</Action><Action id="71">Antihypercholesterolemic agent</Action></ActionsSecondary><Technologies><Technology id="573">Immunoglobulin-G</Technology><Technology id="169">Monoclonal antibody humanized</Technology><Technology id="647">Subcutaneous formulation</Technology><Technology id="761">Biological therapeutic</Technology><Technology id="648">Intravenous formulation</Technology></Technologies><EphmraCodes><Ephmra><Code>C10A</Code><Name>CHOLESTEROL AND TRIGLYCERIDE REDUCTION PREPARATIONS</Name></Ephmra></EphmraCodes><LastModificationDate>2017-09-27T08:37:35.000Z</LastModificationDate><ChangeDateLast>2017-03-16T00:00:00.000Z</ChangeDateLast><AddedDate>2009-10-09T12:19:58.000Z</AddedDate><DevelopmentProfile><Summary><displayLabel>Summary</displayLabel><value>&lt;Summary&gt;&lt;para&gt;&lt;ulink linkID="18767" linkType="Company"&gt;Pfizer&lt;/ulink&gt; (following its acquisition of &lt;ulink linkID="29177" linkType="Company"&gt;Rinat Neuroscience&lt;/ulink&gt;) was developing  bococizumab (RN-316; PF-04950615), a proprotein convertase subtilisin/kexin type 9 (PCSK9)-targeted humanized IgG2deltaA mAb, for the potential injectable  treatment of hypercholesterolemia [&lt;ulink linkID="679198" linkType="Reference"&gt;679198&lt;/ulink&gt;], [&lt;ulink linkID="1048590" linkType="Reference"&gt;1048590&lt;/ulink&gt;], [&lt;ulink linkID="1117490" linkType="Reference"&gt;1117490&lt;/ulink&gt;], [&lt;ulink linkID="1177446" linkType="Reference"&gt;1177446&lt;/ulink&gt;], [&lt;ulink linkID="1337868" linkType="Reference"&gt;1337868&lt;/ulink&gt;]. &lt;/para&gt;&lt;para&gt;In October 2013, a phase III program was initiated, consisting of two cardiovascular outcome studies (SPIRE-1 and SPIRE-2) and multiple lipid-lowering studies  (including SPIRE-HR, SPIRE-FH, SPIRE-LDL, SPIRE-SI, SPIRE-LL and SPIRE-AI) in high-risk patients with hyperlipidemia and in patients with heterozygous familial hypercholesterolemia [&lt;ulink linkID="1493441" linkType="Reference"&gt;1493441&lt;/ulink&gt;], [&lt;ulink linkID="1493442" linkType="Reference"&gt;1493442&lt;/ulink&gt;], [&lt;ulink linkID="1493439" linkType="Reference"&gt;1493439&lt;/ulink&gt;], [&lt;ulink linkID="1635407" linkType="Reference"&gt;1635407&lt;/ulink&gt;]. In February 2016, positive results from the first LDL-lowering study to read out, SPIRE-S1 (in adults intolerant to statins) were reported [&lt;ulink linkID="1731533" linkType="Reference"&gt;1731533&lt;/ulink&gt;], [&lt;ulink linkID="1732627" linkType="Reference"&gt;1732627&lt;/ulink&gt;]. In April 2016, positive data from the SPIRE-AI trial in patients with hyperlipidemia or mixed dyslipidemia and high LDL-C despite statin therapy were reported [&lt;ulink linkID="1748041" linkType="Reference"&gt;1748041&lt;/ulink&gt;]. In June 2016, positive results were reported from the SPIRE-HR and  SPIRE-FH trials in patients at high and very high risk for cardiovascular events; at that time, the two remaining ongoing trials, SPIRE-LDL and SPIRE-LL, were expected to complete later in 2016   [&lt;ulink linkID="1776686" linkType="Reference"&gt;1776686&lt;/ulink&gt;]. However, in November 2016, development of the mAb was discontinued by Pfizer; the company stated that the drug was unlikely to provide value [&lt;ulink linkID="1868464" linkType="Reference"&gt;1868464&lt;/ulink&gt;], [&lt;ulink linkID="1868848" linkType="Reference"&gt;1868848&lt;/ulink&gt;].&lt;/para&gt;&lt;para&gt;By October 2013, Pfizer was planning to initially develop the drug for twice-monthly administration, with a view to potentially exploring a once-monthly schedule [&lt;ulink linkID="1494583" linkType="Reference"&gt;1494583&lt;/ulink&gt;].&lt;/para&gt;&lt;/Summary&gt;</value></Summary><PatentsAndGenerics><displayLabel>Patents and Generics</displayLabel><value>&lt;PatentsAndGenerics&gt;&lt;para&gt;&lt;ulink linkID="PA5538332" linkType="Patent"&gt;US-08080243&lt;/ulink&gt; was granted in December 2012, and is the first of a US patent family covering bococizumab; coverage is provided to September 2029.&lt;/para&gt;&lt;/PatentsAndGenerics&gt;</value></PatentsAndGenerics><Premarketing><displayLabel>Premarketing</displayLabel><value>&lt;Premarketing&gt;&lt;para&gt;&lt;subtitle&gt;Primary hyperlipidemia or mixed dyslipidemia&lt;/subtitle&gt;&lt;subtitle&gt;Phase III&lt;/subtitle&gt;IIn October 2016, an interventional, double blind, placebo controlled, randomized, stratified, parallel group, multi-center, phase III study (&lt;ulink linkID="277754" linkType="Protocol"&gt;NCT02947334&lt;/ulink&gt;: B1481047: SPIRE-ASIA) was planned in China to asses the safety and efficacy of bococizumab (150 mg sc q2w) to placebo in patients (expected n = 750) with primary hyperlipidemia or mixed dyslipidemia. At that time, the study was expected to complete in May 2019 [&lt;ulink linkID="1871992" linkType="Reference"&gt;1871992&lt;/ulink&gt;]. &lt;/para&gt;&lt;para&gt;In August 2015, a double-blind, randomized, placebo-controlled, phase III trial (&lt;ulink linkID="237379" linkType="Protocol"&gt;NCT02524106&lt;/ulink&gt;; B-HIVE; WI204426) was planned to be initiated in December 2015, to assess the safety and efficacy of bococizumab in lowering LDL-C  in HIV-infected subjects (expected n = 200). At that time, the trial was expected to complete in December 2016. In August 2016, the trial was initiated. At that time, the trial was expected to complete in September 2019. In January 2017 the trial was terminated  [&lt;ulink linkID="1687839" linkType="Reference"&gt;1687839&lt;/ulink&gt;].&lt;/para&gt;&lt;para&gt;In June 2015, a 12 week, double-blind, randomized, placebo-controlled, parallel group, phase III study (&lt;ulink linkID="231123" linkType="Protocol"&gt;NCT02458287&lt;/ulink&gt;; B1481046; SPIRE-AI) to evaluate the efficacy, safety, tolerability and actual use of bococizumab and an autoinjector (pre-filled pen) in subjects (expected n 300) with primary hyperlipidemia or mixed dyslipidemia receiving statin therapy and whose LDL-C was &amp;gt;/= 70 mg/dL, was initiated in the US. The study was expected to complete in June 2016 [&lt;ulink linkID="1673477" linkType="Reference"&gt;1673477&lt;/ulink&gt;]. In April 2016, data from 299 patients were reported showing that the study met its co-primary endpoints of percent change from baseline in LDL-C reduction at 12 weeks compared with placebo and proportion of patients successfully operating the pre-filled pen [&lt;ulink linkID="1748041" linkType="Reference"&gt;1748041&lt;/ulink&gt;].&lt;/para&gt;&lt;para&gt;In November 2014, a  double-blind, randomized, placebo-controlled, parallel-group, 52-week, phase III trial (&lt;ulink linkID="180060" linkType="Protocol"&gt;NCT02100514&lt;/ulink&gt;; B1481045; SPIRE-LL; 2014-000478-20) was initiated in  the US, Canada, Norway, UK and  Puerto Rico, in patients (expected n = 690) with hyperlipidemia, to assess the safety and efficacy of bococizumab. At that time, the trial was expected to complete in July 2016 [&lt;ulink linkID="1635407" linkType="Reference"&gt;1635407&lt;/ulink&gt;]. In June 2016, the trial was expected to complete later in 2016 [&lt;ulink linkID="1776686" linkType="Reference"&gt;1776686&lt;/ulink&gt;].&lt;/para&gt;&lt;para&gt;In July 2014, double-blind, randomized, placebo-controlled, parallel-group, phase III trial (&lt;ulink linkID="186156" linkType="Protocol"&gt;NCT02135029&lt;/ulink&gt;; B1481030; SPIRE-SI) was  initiated in the US, in subjects (expected n = 300) with  hyperlipidemia. The trial was expected to complete in October 2015 [&lt;ulink linkID="1584777" linkType="Reference"&gt;1584777&lt;/ulink&gt;]. In February 2016, the company   reported positive topline results (received in January 2016) from the  SPIRE-SI study. The trial met its primary endpoint, as measured by the percent change in baseline LDL-C level at 12 weeks. No new or unexpected safety findings for bococizumab were observed in the study [&lt;ulink linkID="1731533" linkType="Reference"&gt;1731533&lt;/ulink&gt;].&lt;/para&gt;&lt;para&gt;In December 2013,  a double-blind, randomized, placebo-controlled, parallel-group, phase III trial (&lt;ulink linkID="158817" linkType="Protocol"&gt;NCT01968967&lt;/ulink&gt;; B1481020; SPIRE-LDL) was initiated in the US, in subjects (expected n = 1932) with primary hyperlipidemia or mixed dyslipidemia receiving highly effective statins and at risk of cardiovascular events,  to assess the safety, efficacy and tolerability of bococizumab to lower LDL-C. The trial was expected to complete in July 2016  [&lt;ulink linkID="1493442" linkType="Reference"&gt;1493442&lt;/ulink&gt;]. In May 2015, the trial was ongoing in Canada, Europe, Colombia, Mexico and Taiwan [&lt;ulink linkID="1493442" linkType="Reference"&gt;1493442&lt;/ulink&gt;]. In June 2016, the trial was expected to complete later in 2016 [&lt;ulink linkID="1776686" linkType="Reference"&gt;1776686&lt;/ulink&gt;].&lt;/para&gt;&lt;para&gt;In October 2013, a 52-week, double-blind, randomized, placebo-controlled, parallel-group, phase III trial (&lt;ulink linkID="158817" linkType="Protocol"&gt;NCT01968954&lt;/ulink&gt;; B1481019; SPIRE-HR) was initiated in the US, in patients (n = 711) with primary hyperlipidemia or mixed dyslipidemia (ie, with high cholesterol) receiving highly effective statins and at risk of cardiovascular events,  to assess the safety, efficacy and tolerability of bococizumab to lower LDL-C. The trial completes in April 2016 [&lt;ulink linkID="1493441" linkType="Reference"&gt;1493441&lt;/ulink&gt;], [&lt;ulink linkID="1776686" linkType="Reference"&gt;1776686&lt;/ulink&gt;]. In June 2016, data were reported,which showed that  the trial met its primary endpoint. At 12 weeks,  bococizumab achieved a significant reduction in the percent change from baseline in LDL-C compared with placebo in adult  patients at high and very high risk for cardiovascular events who were receiving a maximally tolerated dose of statin  [&lt;ulink linkID="1776686" linkType="Reference"&gt;1776686&lt;/ulink&gt;].&lt;/para&gt;&lt;para&gt;In October 2013, a multicenter, double-blind, randomized, placebo-controlled, parallel-group-assignment, cardiovascular outcomes, phase III  trial (&lt;ulink linkID="159992" linkType="Protocol"&gt;NCT01975389&lt;/ulink&gt;; SPIRE-2; B1481038; CV OUTCOMES 2; 2013-002795-41) was initiated in the US to assess the ability of bococizumab to reduce the occurrence of major cardiovascular events  in high-risk patients (11000)  receiving background lipid-lowering therapy with LDL-C &amp;gt; 100 mg/dl or non-HDL-C &amp;gt;130 mg/dl. The primary endpoint was the time to first occurrence of a major cardiovascular event up to 60 months in patients receiving 150 mg twice monthly [&lt;ulink linkID="1540099" linkType="Reference"&gt;1540099&lt;/ulink&gt;]. In April 2016, enrollment was complete; at that time, the study was expected to complete in 2H17 [&lt;ulink linkID="1756059" linkType="Reference"&gt;1756059&lt;/ulink&gt;].  In November 2016, the trial was stopped due to the discontinuation of  drug development [&lt;ulink linkID="1868848" linkType="Reference"&gt;1868848&lt;/ulink&gt;].&lt;/para&gt;&lt;para&gt;In October 2013, a double-blind, randomized, placebo-controlled, parallel-group-assignment, cardiovascular outcomes, phase III  trial (&lt;ulink linkID="160043" linkType="Protocol"&gt;NCT01975376&lt;/ulink&gt;; SPIRE-1) was initiated in high-risk subjects receiving background lipid-lowering therapy with LDL-C &amp;gt; 70 and &amp;lt;100 mg/dl , or non-HDL-C &amp;gt;100 and &amp;lt;130 mg/dl. The primary endpoint was cardiovascular event to 60 months in patients receiving 150 mg twice monthly. The trial was to enroll 12,000 patients and complete in August 2017. In October 2016,  the trial was ongoing in patients (expected n = 17000) with   cardiovascular disease including cardiovascular death, myocardial infarction, stroke and unstable angina. At that time, the trial was expected to complete in June 2018 [&lt;ulink linkID="1540104" linkType="Reference"&gt;1540104&lt;/ulink&gt;]. In November 2016, the trial was stopped due to the discontinuation of  drug development [&lt;ulink linkID="1868848" linkType="Reference"&gt;1868848&lt;/ulink&gt;].&lt;/para&gt;&lt;para&gt;&lt;subtitle&gt;Phase II&lt;/subtitle&gt;In April 2014, a phase II randomized, double blind, parallel group, placebo controlled, dose ranging, efficacy, tolerability and safety study (&lt;ulink linkID="171679" linkType="Protocol"&gt;NCT02055976&lt;/ulink&gt;; B1481036) of PF-04950615 following twice monthly sc doses was initiated in hypercholesterolemic Japanese subjects (expected n = 216) who were receiving a stable dose of atorvastatin or treatment naive; at that time, the study was expected to complete in December 2014 [&lt;ulink linkID="1566895" linkType="Reference"&gt;1566895&lt;/ulink&gt;].&lt;/para&gt;&lt;para&gt;In July 2012, a randomized double-blind dose-ranging phase IIb trial (&lt;ulink linkID="87215" linkType="Protocol"&gt;NCT01592240&lt;/ulink&gt;) began to assess the safety, efficacy and tolerability of different doses of once- (200 mg or 300 mg) and twice-monthly (50 mg, 100 mg or 150 mg) sc bococizumab in hypercholesterolemic subjects on a statin. The primary endpoint was absolute change in LDL-C. The trial was to enroll 356 patients and completed in May 2013 [&lt;ulink linkID="1540127" linkType="Reference"&gt;1540127&lt;/ulink&gt;]. In March 2014, data were presented at the 63rd Annual Meeting of the American College of Cardiology in Washington DC. Bococizumab twice and once monthly dosing regimens were associated with significant placebo-adjusted reductions in LDL-C at week 12, with the greatest reductions seen with 150 mg for the twice monthly regimen (-53.4 mg/dL) and 300 mg for the once monthly regimen (-44.9 mg/dL) [&lt;ulink linkID="1540048" linkType="Reference"&gt;1540048&lt;/ulink&gt;], [&lt;ulink linkID="1542825" linkType="Reference"&gt;1542825&lt;/ulink&gt;].&lt;/para&gt;&lt;para&gt;In July 2011, two randomized, double-blind, placebo-controlled, phase II studies began: (&lt;ulink linkID="77233" linkType="Protocol"&gt;NCT01350141&lt;/ulink&gt;; B1481012) in hypercholesterolemic patients receiving maximum doses of &lt;ulink linkID="2807" linkType="Drug"&gt;atorvastatin&lt;/ulink&gt; or &lt;ulink linkID="12420" linkType="Drug"&gt;rosuvastatin&lt;/ulink&gt; (n = 46) in the US, to assess the safety and efficacy of iv bococizumab, which was completed in June 2012 [&lt;ulink linkID="1210723" linkType="Reference"&gt;1210723&lt;/ulink&gt;].  And (&lt;ulink linkID="76878" linkType="Protocol"&gt;NCT01342211&lt;/ulink&gt;; B1481005) in hypercholesterolemic patients receiving high doses of atorvastatin, rosuvastatin or &lt;ulink linkID="44313" linkType="Drug"&gt;simvastatin&lt;/ulink&gt; (n = 111) in the US and Canada, to assess the safety and efficacy of iv bococizumab, which was completed in July 2012 [&lt;ulink linkID="1210726" linkType="Reference"&gt;1210726&lt;/ulink&gt;]. In November 2012, pooled data from  &lt;ulink linkID="77233" linkType="Protocol"&gt;NCT01350141&lt;/ulink&gt; and &lt;ulink linkID="76878" linkType="Protocol"&gt;NCT01342211&lt;/ulink&gt; were presented at the AHA Scientific Sessions in Los Angeles, CA; data showed bococizumab robustly decreases LDL-and total cholesterol at 3 and 6 mg. A minor but significant increase in HDL-cholesterol was observed with these two  doses. The effect was maintained during the 4-week dosing interval with the 3- and 6-mg doses of bococizumab, and clearance of the effect by 8 weeks after the last dose was seen. Bococizumab was well tolerated [&lt;ulink linkID="1337868" linkType="Reference"&gt;1337868&lt;/ulink&gt;], [&lt;ulink linkID="1337801" linkType="Reference"&gt;1337801&lt;/ulink&gt;]. &lt;/para&gt;&lt;para&gt;&lt;subtitle&gt;Heterozygous familial hypercholesterolemia&lt;/subtitle&gt;In October 2013, a 52-week, double-blind, randomized, placebo-controlled, parallel-group, phase III trial (&lt;ulink linkID="158822" linkType="Protocol"&gt;NCT01968980&lt;/ulink&gt;; B1481021; SPIRE-FH) was initiated in the US in patients (n = 370) with heterozygous familial hypercholesterolemia receiving highly effective statins, to assess the safety, efficacy and tolerability of bococizumab to lower LDL-C. The trial complete in April 2016 [&lt;ulink linkID="1493439" linkType="Reference"&gt;1493439&lt;/ulink&gt;], [&lt;ulink linkID="1776686" linkType="Reference"&gt;1776686&lt;/ulink&gt;]. In June 2016, data were reported, which showed that the trial met its primary endpoint. At 12 weeks, bococizumab achieved a significant reduction in the percent change from baseline in LDL-C compared with placebo in adult  patients at high and very high risk for cardiovascular events who were receiving a maximally tolerated dose of statin and were to form part of  a potential future regulatory filing [&lt;ulink linkID="1776686" linkType="Reference"&gt;1776686&lt;/ulink&gt;].&lt;/para&gt;&lt;para&gt;&lt;subtitle&gt;Phase I studies&lt;/subtitle&gt;In  February 2016, in collaboration with &lt;ulink linkID="1010825" linkType="Company"&gt;Halozyme Therapeutics&lt;/ulink&gt;, the first patient was dosed in an open-label, single-dose, randomized, dose-escalation,   phase I trial (&lt;ulink linkID="251901" linkType="Protocol"&gt;NCT02667223&lt;/ulink&gt;; B1481051 2015-003568-36) that was initiated in Belgium   in healthy volunteers and patients (expected n = 75) with hypercholesterolemia,   to assess  the pharmacokinetics and pharmacodynamics of bococizumab alone and in combination with Halozyme's proprietary recombinant human hyaluronidase.  The trial aimed to optimize the  delivery and frequency of bococizumab injections. At that time, the trial was expected to complete in July 2016  [&lt;ulink linkID="1733085" linkType="Reference"&gt;1733085&lt;/ulink&gt;], [&lt;ulink linkID="1743111" linkType="Reference"&gt;1743111&lt;/ulink&gt;]; however,  that  month, the trial was terminated  due to business priorities regarding study execution  [&lt;ulink linkID="1733085" linkType="Reference"&gt;1733085&lt;/ulink&gt;]. &lt;/para&gt;&lt;para&gt;In February 2014, a clinical trial application was filed in China, presumed to be for    hypercholesterolemia [&lt;ulink linkID="1530637" linkType="Reference"&gt;1530637&lt;/ulink&gt;], [&lt;ulink linkID="1523013" linkType="Reference"&gt;1523013&lt;/ulink&gt;].&lt;/para&gt;&lt;para&gt;In November 2012, data from a multiple-dose, double-blind, placebo-controlled, parallel-design phase I study were presented at the AHA Scientific Sessions in Los Angeles, CA. Patients of non-Japanese and Japanese were randomized to receive bococizumab (0.25, 0.5, 1.0, and 1.5 mg /kg iv infusion qw; n = 55) or placebo (n = 12). When compared with placebo, the day 29 mean percentage changes in LDL-cholesterol, total cholesterol, HDL-cholesterol, and triglycerides were found to be greater with all doses of bococizumab. The ethnicity showed no clinically-meaningful effect on the pharmacokinetics. Bococizumab was safe and well tolerated [&lt;ulink linkID="1337858" linkType="Reference"&gt;1337858&lt;/ulink&gt;]. &lt;/para&gt;&lt;para&gt;In July 2010, a non-randomized, open-label, phase I study (&lt;ulink linkID="68304" linkType="Protocol"&gt;NCT01163851&lt;/ulink&gt;; B1481003) was initiated in hypercholesterolemic patients receiving atorvastatin therapy (expected n = 20), to assess the pharmacokinetics, pharmacodynamics and safety of bococizumab. The study was  completed in April  2011 [&lt;ulink linkID="1117490" linkType="Reference"&gt;1117490&lt;/ulink&gt;]. &lt;/para&gt;&lt;para&gt;In January 2010, a randomized, double-blind, phase I study (&lt;ulink linkID="60887" linkType="Protocol"&gt;NCT00991159&lt;/ulink&gt;; B1481001; RN316-101) was initiated in healthy volunteers (expected n = 48), to assess the safety, tolerability, pharmacokinetics and pharmacodynamics of single-escalating-doses of iv bococizumab. The study was completed in June 2010 [&lt;ulink linkID="1048590" linkType="Reference"&gt;1048590&lt;/ulink&gt;].&lt;/para&gt;&lt;/Premarketing&gt;</value></Premarketing><Preclinical><displayLabel>Preclinical</displayLabel><value>&lt;Preclinical&gt;&lt;para&gt;In March 2015, preclinical data were presented at the 54th Society of Toxicology Annual Meeting in San Diego, CA. Bococizumab exhibited no adverse effects on embryo-fetal development in the presence of significant reductions in both maternal and fetal cholesterol concentrations in pregnant Sprague Dawley rats [&lt;ulink linkID="1651842" linkType="Reference"&gt;1651842&lt;/ulink&gt;].&lt;/para&gt;&lt;/Preclinical&gt;</value></Preclinical><AdditionalInformation><displayLabel>Additional Information</displayLabel><value>&lt;AdditionalInformation&gt;&lt;para&gt;In February 2014, the EMA's Pediatric Committee (PDCO) adopted a positive opinion agreeing a pediatric investigation plan for   bococizumab for the treatment of elevated cholesterol and mixed dyslipidemia and the prevention of cardiovascular events in patients with cardiovascular disease or cardiovascular disease risk equivalent [&lt;ulink linkID="1528112" linkType="Reference"&gt;1528112&lt;/ulink&gt;].&lt;/para&gt;&lt;/AdditionalInformation&gt;</value></AdditionalInformation></DevelopmentProfile><IDdbDevelopmentStatus><DevelopmentStatusCurrent><Company id="18767">Pfizer Inc</Company><Country id="ZA">South Africa</Country><DevelopmentStatus id="DX" sortOrder="4">Discontinued</DevelopmentStatus><DiscontinuedReason id="2">Lack of Activity or Efficacy</DiscontinuedReason><Indication id="175">Hyperlipidemia</Indication><StatusDate>2016-11-01T00:00:00.000Z</StatusDate><Source id="1868464" type="CORPORATE"/></DevelopmentStatusCurrent><DevelopmentStatusCurrent><Company id="18767">Pfizer Inc</Company><Country id="KR">South Korea</Country><DevelopmentStatus id="DX" sortOrder="4">Discontinued</DevelopmentStatus><DiscontinuedReason id="2">Lack of Activity or Efficacy</DiscontinuedReason><Indication id="175">Hyperlipidemia</Indication><StatusDate>2016-11-01T00:00:00.000Z</StatusDate><Source id="1868464" type="CORPORATE"/></DevelopmentStatusCurrent><DevelopmentStatusCurrent><Company id="18767">Pfizer Inc</Company><Country id="US">US</Country><DevelopmentStatus id="DX" sortOrder="4">Discontinued</DevelopmentStatus><DiscontinuedReason id="2">Lack of Activity or Efficacy</DiscontinuedReason><Indication id="175">Hyperlipidemia</Indication><StatusDate>2016-11-01T00:00:00.000Z</StatusDate><Source id="1868464" type="CORPORATE"/></DevelopmentStatusCurrent><DevelopmentStatusCurrent><Company id="18767">Pfizer Inc</Company><Country id="CA">Canada</Country><DevelopmentStatus id="DX" sortOrder="4">Discontinued</DevelopmentStatus><DiscontinuedReason id="2">Lack of Activity or Efficacy</DiscontinuedReason><Indication id="174">Hypercholesterolemia</Indication><StatusDate>2016-11-01T00:00:00.000Z</StatusDate><Source id="1868464" type="CORPORATE"/></DevelopmentStatusCurrent><DevelopmentStatusCurrent><Company id="18767">Pfizer Inc</Company><Country id="US">US</Country><DevelopmentStatus id="DX" sortOrder="4">Discontinued</DevelopmentStatus><DiscontinuedReason id="2">Lack of Activity or Efficacy</DiscontinuedReason><Indication id="3204">Familial hypercholesterolemia</Indication><StatusDate>2016-11-01T00:00:00.000Z</StatusDate><Source id="1868464" type="CORPORATE"/></DevelopmentStatusCurrent><DevelopmentStatusCurrent><Company id="18767">Pfizer Inc</Company><Country id="XE">South America</Country><DevelopmentStatus id="DX" sortOrder="4">Discontinued</DevelopmentStatus><DiscontinuedReason id="2">Lack of Activity or Efficacy</DiscontinuedReason><Indication id="175">Hyperlipidemia</Indication><StatusDate>2016-11-01T00:00:00.000Z</StatusDate><Source id="1868464" type="CORPORATE"/></DevelopmentStatusCurrent><DevelopmentStatusCurrent><Company id="18767">Pfizer Inc</Company><Country id="X5">Europe</Country><DevelopmentStatus id="DX" sortOrder="4">Discontinued</DevelopmentStatus><DiscontinuedReason id="2">Lack of Activity or Efficacy</DiscontinuedReason><Indication id="175">Hyperlipidemia</Indication><StatusDate>2016-11-01T00:00:00.000Z</StatusDate><Source id="1868464" type="CORPORATE"/></DevelopmentStatusCurrent><DevelopmentStatusCurrent><Company id="18767">Pfizer Inc</Company><Country id="JP">Japan</Country><DevelopmentStatus id="DX" sortOrder="4">Discontinued</DevelopmentStatus><DiscontinuedReason id="2">Lack of Activity or Efficacy</DiscontinuedReason><Indication id="174">Hypercholesterolemia</Indication><StatusDate>2016-11-01T00:00:00.000Z</StatusDate><Source id="1868464" type="CORPORATE"/></DevelopmentStatusCurrent><DevelopmentStatusCurrent><Company id="18767">Pfizer Inc</Company><Country id="CA">Canada</Country><DevelopmentStatus id="DX" sortOrder="4">Discontinued</DevelopmentStatus><DiscontinuedReason id="2">Lack of Activity or Efficacy</DiscontinuedReason><Indication id="175">Hyperlipidemia</Indication><StatusDate>2016-11-01T00:00:00.000Z</StatusDate><Source id="1868464" type="CORPORATE"/></DevelopmentStatusCurrent><DevelopmentStatusCurrent><Company id="18767">Pfizer Inc</Company><Country id="BE">Belgium</Country><DevelopmentStatus id="DX" sortOrder="4">Discontinued</DevelopmentStatus><DiscontinuedReason id="2">Lack of Activity or Efficacy</DiscontinuedReason><Indication id="174">Hypercholesterolemia</Indication><StatusDate>2016-11-01T00:00:00.000Z</StatusDate><Source id="1868464" type="CORPORATE"/></DevelopmentStatusCurrent><DevelopmentStatusCurrent><Company id="18767">Pfizer Inc</Company><Country id="CN">China</Country><DevelopmentStatus id="DX" sortOrder="4">Discontinued</DevelopmentStatus><DiscontinuedReason id="2">Lack of Activity or Efficacy</DiscontinuedReason><Indication id="174">Hypercholesterolemia</Indication><StatusDate>2016-11-01T00:00:00.000Z</StatusDate><Source id="1868464" type="CORPORATE"/></DevelopmentStatusCurrent><DevelopmentStatusCurrent><Company id="18767">Pfizer Inc</Company><Country id="X2">Asia</Country><DevelopmentStatus id="DX" sortOrder="4">Discontinued</DevelopmentStatus><DiscontinuedReason id="2">Lack of Activity or Efficacy</DiscontinuedReason><Indication id="175">Hyperlipidemia</Indication><StatusDate>2016-11-01T00:00:00.000Z</StatusDate><Source id="1868464" type="CORPORATE"/></DevelopmentStatusCurrent><DevelopmentStatusCurrent><Company id="18767">Pfizer Inc</Company><Country id="US">US</Country><DevelopmentStatus id="DX" sortOrder="4">Discontinued</DevelopmentStatus><DiscontinuedReason id="2">Lack of Activity or Efficacy</DiscontinuedReason><Indication id="174">Hypercholesterolemia</Indication><StatusDate>2016-11-01T00:00:00.000Z</StatusDate><Source id="1868464" type="CORPORATE"/></DevelopmentStatusCurrent><DevelopmentStatusCurrent><Company id="18767">Pfizer Inc</Company><Country id="X4">Australia and New Zealand</Country><DevelopmentStatus id="DX" sortOrder="4">Discontinued</DevelopmentStatus><DiscontinuedReason id="2">Lack of Activity or Efficacy</DiscontinuedReason><Indication id="175">Hyperlipidemia</Indication><StatusDate>2016-11-01T00:00:00.000Z</StatusDate><Source id="1868464" type="CORPORATE"/></DevelopmentStatusCurrent><DevelopmentStatusHistoric><Company id="18767">Pfizer Inc</Company><Country id="US">US</Country><DevelopmentStatus id="C2" sortOrder="11">Phase 2 Clinical</DevelopmentStatus><Indication id="174">Hypercholesterolemia</Indication><StatusDate>2011-07-26T00:00:00.000Z</StatusDate><Source id="1210723" type="TRIALREG"/></DevelopmentStatusHistoric><DevelopmentStatusHistoric><Company id="18767">Pfizer Inc</Company><Country id="BE">Belgium</Country><DevelopmentStatus id="DR" sortOrder="7">Discovery</DevelopmentStatus><Indication id="174">Hypercholesterolemia</Indication><StatusDate>2016-01-06T00:00:00.000Z</StatusDate><Source id="1733085" type="TRIALREG"/></DevelopmentStatusHistoric><DevelopmentStatusHistoric><Company id="18767">Pfizer Inc</Company><Country id="BE">Belgium</Country><DevelopmentStatus id="C1" sortOrder="10">Phase 1 Clinical</DevelopmentStatus><Indication id="174">Hypercholesterolemia</Indication><StatusDate>2016-02-23T00:00:00.000Z</StatusDate><Source id="1733085" type="TRIALREG"/></DevelopmentStatusHistoric><DevelopmentStatusHistoric><Company id="18767">Pfizer Inc</Company><Country id="CA">Canada</Country><DevelopmentStatus id="C2" sortOrder="11">Phase 2 Clinical</DevelopmentStatus><Indication id="174">Hypercholesterolemia</Indication><StatusDate>2011-07-26T00:00:00.000Z</StatusDate><Source id="1210726" type="TRIALREG"/></DevelopmentStatusHistoric><DevelopmentStatusHistoric><Company id="18767">Pfizer Inc</Company><Country id="JP">Japan</Country><DevelopmentStatus id="C2" sortOrder="11">Phase 2 Clinical</DevelopmentStatus><Indication id="174">Hypercholesterolemia</Indication><StatusDate>2014-04-30T00:00:00.000Z</StatusDate><Source id="1566895" type="TRIALREG"/></DevelopmentStatusHistoric><DevelopmentStatusHistoric><Company id="18767">Pfizer Inc</Company><Country id="CA">Canada</Country><DevelopmentStatus id="C3" sortOrder="12">Phase 3 Clinical</DevelopmentStatus><Indication id="175">Hyperlipidemia</Indication><StatusDate>2014-11-09T00:00:00.000Z</StatusDate></DevelopmentStatusHistoric><DevelopmentStatusHistoric><Company id="18767">Pfizer Inc</Company><Country id="X2">Asia</Country><DevelopmentStatus id="C3" sortOrder="12">Phase 3 Clinical</DevelopmentStatus><Indication id="175">Hyperlipidemia</Indication><StatusDate>2015-05-20T00:00:00.000Z</StatusDate><Source id="1493442" type="TRIALREG"/></DevelopmentStatusHistoric><DevelopmentStatusHistoric><Company id="18767">Pfizer Inc</Company><Country id="XE">South America</Country><DevelopmentStatus id="C3" sortOrder="12">Phase 3 Clinical</DevelopmentStatus><Indication id="175">Hyperlipidemia</Indication><StatusDate>2015-05-20T00:00:00.000Z</StatusDate><Source id="1493442" type="TRIALREG"/></DevelopmentStatusHistoric><DevelopmentStatusHistoric><Company id="18767">Pfizer Inc</Company><Country id="X4">Australia and New Zealand</Country><DevelopmentStatus id="C3" sortOrder="12">Phase 3 Clinical</DevelopmentStatus><Indication id="175">Hyperlipidemia</Indication><StatusDate>2015-05-20T00:00:00.000Z</StatusDate><Source id="1493442" type="TRIALREG"/></DevelopmentStatusHistoric><DevelopmentStatusHistoric><Company id="18767">Pfizer Inc</Company><Country id="US">US</Country><DevelopmentStatus id="C3" sortOrder="12">Phase 3 Clinical</DevelopmentStatus><Indication id="3204">Familial hypercholesterolemia</Indication><StatusDate>2013-10-25T00:00:00.000Z</StatusDate><Source id="1493439" type="TRIALREG"/></DevelopmentStatusHistoric><DevelopmentStatusHistoric><Company id="18767">Pfizer Inc</Company><Country id="X5">Europe</Country><DevelopmentStatus id="C3" sortOrder="12">Phase 3 Clinical</DevelopmentStatus><Indication id="175">Hyperlipidemia</Indication><StatusDate>2014-11-09T00:00:00.000Z</StatusDate></DevelopmentStatusHistoric><DevelopmentStatusHistoric><Company id="18767">Pfizer Inc</Company><Country id="US">US</Country><DevelopmentStatus id="C3" sortOrder="12">Phase 3 Clinical</DevelopmentStatus><Indication id="175">Hyperlipidemia</Indication><StatusDate>2014-07-24T00:00:00.000Z</StatusDate><Source id="1584777" type="TRIALREG"/></DevelopmentStatusHistoric><DevelopmentStatusHistoric><Company id="18767">Pfizer Inc</Company><Country id="US">US</Country><DevelopmentStatus id="C3" sortOrder="12">Phase 3 Clinical</DevelopmentStatus><Indication id="174">Hypercholesterolemia</Indication><StatusDate>2013-10-25T00:00:00.000Z</StatusDate><Source id="1493441" type="TRIALREG"/></DevelopmentStatusHistoric><DevelopmentStatusHistoric><Company id="18767">Pfizer Inc</Company><Country id="KR">South Korea</Country><DevelopmentStatus id="C3" sortOrder="12">Phase 3 Clinical</DevelopmentStatus><Indication id="175">Hyperlipidemia</Indication><StatusDate>2014-11-09T00:00:00.000Z</StatusDate></DevelopmentStatusHistoric><DevelopmentStatusHistoric><Company id="18767">Pfizer Inc</Company><Country id="CN">China</Country><DevelopmentStatus id="DR" sortOrder="7">Discovery</DevelopmentStatus><Indication id="174">Hypercholesterolemia</Indication><StatusDate>2014-02-28T00:00:00.000Z</StatusDate><Source id="1530637" type="OTHER"/></DevelopmentStatusHistoric><DevelopmentStatusHistoric><Company id="18767">Pfizer Inc</Company><Country id="ZA">South Africa</Country><DevelopmentStatus id="C3" sortOrder="12">Phase 3 Clinical</DevelopmentStatus><Indication id="175">Hyperlipidemia</Indication><StatusDate>2013-11-26T00:00:00.000Z</StatusDate><Source id="1540099" type="TRIALREG"/></DevelopmentStatusHistoric><DevelopmentStatusHistoric><Company id="18767">Pfizer Inc</Company><Country id="US">US</Country><DevelopmentStatus id="DR" sortOrder="7">Discovery</DevelopmentStatus><Indication id="174">Hypercholesterolemia</Indication><StatusDate>2007-04-15T00:00:00.000Z</StatusDate><Source id="1131022" type="SERIAL"/></DevelopmentStatusHistoric><DevelopmentStatusHistoric><Company id="18767">Pfizer Inc</Company><Country id="US">US</Country><DevelopmentStatus id="C1" sortOrder="10">Phase 1 Clinical</DevelopmentStatus><Indication id="174">Hypercholesterolemia</Indication><StatusDate>2010-01-08T00:00:00.000Z</StatusDate><Source id="1048590" type="TRIALREG"/></DevelopmentStatusHistoric></IDdbDevelopmentStatus><Targets><Target id="PTGT-08850"><Name>Proprotein convertase PC9</Name><SwissprotNumbers><Swissprot>A8T644</Swissprot><Swissprot>A8T650</Swissprot><Swissprot>A8T655</Swissprot><Swissprot>A8T658</Swissprot><Swissprot>A8T662</Swissprot><Swissprot>A8T666</Swissprot><Swissprot>A8T672</Swissprot><Swissprot>A8T677</Swissprot><Swissprot>A8T682</Swissprot><Swissprot>A8T688</Swissprot><Swissprot>A8T695</Swissprot><Swissprot>A8T6A1</Swissprot><Swissprot>A8T6A6</Swissprot><Swissprot>P59996</Swissprot><Swissprot>Q80W65</Swissprot><Swissprot>Q8NBP7</Swissprot></SwissprotNumbers></Target></Targets><ReasonsForUpdate><ReasonForUpdate><Reason>Editorial Amendments</Reason><Description>Minor editorial amendment</Description></ReasonForUpdate></ReasonsForUpdate><CountsByCompanies><Company><Company id="1010825">Halozyme Therapeutics Inc</Company><CountAsPrincipalActive>0</CountAsPrincipalActive><CountAsPrincipalInactive>0</CountAsPrincipalInactive><CountAsPartnerActive>0</CountAsPartnerActive><CountAsPartnerInactive>0</CountAsPartnerInactive><CountTotal>1</CountTotal></Company><Company><Company id="18767">Pfizer Inc</Company><CountAsPrincipalActive>2</CountAsPrincipalActive><CountAsPrincipalInactive>0</CountAsPrincipalInactive><CountAsPartnerActive>2</CountAsPartnerActive><CountAsPartnerInactive>0</CountAsPartnerInactive><CountTotal>2</CountTotal></Company><Company><Company id="20547">University of California</Company><CountAsPrincipalActive>0</CountAsPrincipalActive><CountAsPrincipalInactive>0</CountAsPrincipalInactive><CountAsPartnerActive>0</CountAsPartnerActive><CountAsPartnerInactive>0</CountAsPartnerInactive><CountTotal>1</CountTotal></Company></CountsByCompanies><CountsByTypes><Type><Type sortOrder="2">Drug - Screening/Evaluation</Type><CountActive>1</CountActive><CountInactive>0</CountInactive><CountTotal>1</CountTotal></Type><Type><Type sortOrder="8">Technology - Delivery/Formulation</Type><CountActive>1</CountActive><CountInactive>0</CountInactive><CountTotal>1</CountTotal></Type></CountsByTypes><Deals><Deal id="143147" title="Pfizer to use Halozyme's rHuPH20 technology to develop and commercialize subcutaneous biologics worldwide                     "/><Deal id="157418" title="University of California to provide services to Pfizer to develop bococizumab against hypercholesterolemia     "/></Deals><PatentFamilies><PatentFamily id="1188778" number="WO-2010029513" title="PCSK9 antagonists"/><PatentFamily id="1552311" number="WO-2011111007" title="Antibodies with pH dependent antigen binding"/><PatentFamily id="2455226" number="WO-2013008185" title="Treatment with anti-PCSK9 antibodies"/><PatentFamily id="2636711" number="WO-2013170367" title="Methods and uses for proprotein convert ase subtilisin kexin 9 (PCSK9) inhibitors"/><PatentFamily id="2855290" number="US-20150004174" title="Methods for treating homozygous familial hypercholesterolemia"/><PatentFamily id="3152285" number="WO-2016046684" title="Treatment with anti-PSCK9 antibodies"/><PatentFamily id="3434260" number="WO-2016176089" title="Methods and compositions for reversing disruption of the glycocalyx, inflammation, and oxidative damage"/><PatentFamily id="3560442" number="US-20170056504" title="Method of extending half-life of crystaline antibodies"/><PatentFamily id="3560574" number="US-10072065" title="Peptide-mediated delivery of immunoglobulins across the blood-brain barrier"/><PatentFamily id="3563780" number="WO-2017044665" title="PCSK9 antibody preparations for delivery into a lumen of the intestinal tract using a swallowable drug delivery device"/><PatentFamily id="3586832" number="WO-2017051273" title="Method of preparing a therapeutic protein formulation and antibody formulation produced by such a method"/><PatentFamily id="4542338" number="WO-2019110691" title="Selecting for developability of polypeptide drugs in eukaryotic cell display systems"/></PatentFamilies><PatentFamilyCountsByTypes><PatentFamilyCountsByType><Type sortorder="10">Process</Type><Count>1</Count></PatentFamilyCountsByType><PatentFamilyCountsByType><Type sortorder="12">Product</Type><Count>1</Count></PatentFamilyCountsByType><PatentFamilyCountsByType><Type sortorder="3">Component of Combination</Type><Count>4</Count></PatentFamilyCountsByType><PatentFamilyCountsByType><Type sortorder="5">Formulation</Type><Count>3</Count></PatentFamilyCountsByType><PatentFamilyCountsByType><Type sortorder="8">General interest</Type><Count>2</Count></PatentFamilyCountsByType><PatentFamilyCountsByType><Type sortorder="9">New use</Type><Count>5</Count></PatentFamilyCountsByType></PatentFamilyCountsByTypes><PatentFamilyCountsByCompanies><PatentFamilyCountsByCompany><CompanyLink nameDisplay="InCube Laboratories LLC" id="1052196"/><CountAsOwner>1</CountAsOwner><CountAsThirdParty>0</CountAsThirdParty><CountTotal>1</CountTotal></PatentFamilyCountsByCompany><PatentFamilyCountsByCompany><CompanyLink nameDisplay="Rani Therapeutics LLC" id="1076978"/><CountAsOwner>1</CountAsOwner><CountAsThirdParty>1</CountAsThirdParty><CountTotal>1</CountTotal></PatentFamilyCountsByCompany><PatentFamilyCountsByCompany><CompanyLink nameDisplay="VA Boston Healthcare System" id="1093003"/><CountAsOwner>0</CountAsOwner><CountAsThirdParty>1</CountAsThirdParty><CountTotal>1</CountTotal></PatentFamilyCountsByCompany><PatentFamilyCountsByCompany><CompanyLink nameDisplay="Iontas Ltd" id="1097461"/><CountAsOwner>1</CountAsOwner><CountAsThirdParty>0</CountAsThirdParty><CountTotal>1</CountTotal></PatentFamilyCountsByCompany><PatentFamilyCountsByCompany><CompanyLink nameDisplay="Ganderland &amp; Associates Inc" id="1119261"/><CountAsOwner>0</CountAsOwner><CountAsThirdParty>1</CountAsThirdParty><CountTotal>1</CountTotal></PatentFamilyCountsByCompany><PatentFamilyCountsByCompany><CompanyLink nameDisplay="Kardiatonos Inc" id="1127707"/><CountAsOwner>1</CountAsOwner><CountAsThirdParty>1</CountAsThirdParty><CountTotal>2</CountTotal></PatentFamilyCountsByCompany><PatentFamilyCountsByCompany><CompanyLink nameDisplay="Amgen Inc" id="14109"/><CountAsOwner>1</CountAsOwner><CountAsThirdParty>1</CountAsThirdParty><CountTotal>2</CountTotal></PatentFamilyCountsByCompany><PatentFamilyCountsByCompany><CompanyLink nameDisplay="Pfizer Inc" id="18767"/><CountAsOwner>5</CountAsOwner><CountAsThirdParty>0</CountAsThirdParty><CountTotal>5</CountTotal></PatentFamilyCountsByCompany><PatentFamilyCountsByCompany><CompanyLink nameDisplay="University of British Columbia" id="20532"/><CountAsOwner>1</CountAsOwner><CountAsThirdParty>0</CountAsThirdParty><CountTotal>1</CountTotal></PatentFamilyCountsByCompany><PatentFamilyCountsByCompany><CompanyLink nameDisplay="Boston University" id="20539"/><CountAsOwner>0</CountAsOwner><CountAsThirdParty>1</CountAsThirdParty><CountTotal>1</CountTotal></PatentFamilyCountsByCompany><PatentFamilyCountsByCompany><CompanyLink nameDisplay="Brown University" id="20545"/><CountAsOwner>0</CountAsOwner><CountAsThirdParty>1</CountAsThirdParty><CountTotal>1</CountTotal></PatentFamilyCountsByCompany><PatentFamilyCountsByCompany><CompanyLink nameDisplay="University of California" id="20547"/><CountAsOwner>0</CountAsOwner><CountAsThirdParty>1</CountAsThirdParty><CountTotal>1</CountTotal></PatentFamilyCountsByCompany><PatentFamilyCountsByCompany><CompanyLink nameDisplay="University of Cambridge" id="20550"/><CountAsOwner>0</CountAsOwner><CountAsThirdParty>1</CountAsThirdParty><CountTotal>1</CountTotal></PatentFamilyCountsByCompany><PatentFamilyCountsByCompany><CompanyLink nameDisplay="Mayo Clinic Foundation" id="21111"/><CountAsOwner>1</CountAsOwner><CountAsThirdParty>0</CountAsThirdParty><CountTotal>1</CountTotal></PatentFamilyCountsByCompany><PatentFamilyCountsByCompany><CompanyLink nameDisplay="Individual" id="21144"/><CountAsOwner>2</CountAsOwner><CountAsThirdParty>0</CountAsThirdParty><CountTotal>2</CountTotal></PatentFamilyCountsByCompany><PatentFamilyCountsByCompany><CompanyLink nameDisplay="Harvard Medical School" id="24839"/><CountAsOwner>0</CountAsOwner><CountAsThirdParty>1</CountAsThirdParty><CountTotal>1</CountTotal></PatentFamilyCountsByCompany></PatentFamilyCountsByCompanies><hasSWOTs>N</hasSWOTs></Drug></drugRecordsOutput>